ERBB2 and prostate cancer: Similar results were observed in HER2+ BC, urothelial cancer, and prostate cancer, in which 68Ga-MY6349 PET/CT showed a greater TBR and more tumor lesions than did 18F-FDG PET/CT (Table 1).